Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

NCT03575806 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Malignant Neoplasm

Interventions

COMBINATION_PRODUCT: TACE plus autologous Tcm immunotherapy
PROCEDURE: TACE

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]